Literature DB >> 19407842

Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.

K Ghasemi Falavarjani1, M Modarres, H Nazari.   

Abstract

PURPOSE: To evaluate the effect of intra-silicone injection of bevacizumab for the treatment of neovascular glaucoma (NVG) after vitrectomy for advanced proliferative diabetic retinopathy.
METHODS: Bevacizumab was injected into the silicone oil in five pseudophakic eyes of five patients with NVG. The iris neovascularization (INV) and NVG had developed 1.5-4 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of INV, intraocular pressure and visual acuity.
RESULTS: In all eyes, INV regressed and intraocular pressure was controlled within 7 days. Visual acuity improved in all eyes. In one patient, INV and NVG recurred 10 weeks after the injection and was successfully treated with a repeat intra-silicone bevacizumab injection.
CONCLUSION: Intra-silicone injection of bevacizumab is effective in the treatment of patients with INV and NVG after vitrectomy for advanced proliferative diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19407842     DOI: 10.1038/eye.2009.94

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  15 in total

1.  Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation.

Authors:  Jay Chhablani; Raja Narayanan
Journal:  BMJ Case Rep       Date:  2015-04-13

2.  Editor's choice--top papers of 2010.

Authors:  A Lotery
Journal:  Eye (Lond)       Date:  2011-05       Impact factor: 3.775

3.  Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.

Authors:  Ira Seibel; Annette Hager; Tobias Duncker; Aline I Riechardt; Daniela Nürnberg; Julian P Klein; Matus Rehak; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-07       Impact factor: 3.117

4.  Safety and complications of intravitreal injections performed in an Asian population in Singapore.

Authors:  Yanping Xu; Colin S Tan
Journal:  Int Ophthalmol       Date:  2016-05-28       Impact factor: 2.031

5.  Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade.

Authors:  Yu Xu; Yongsheng You; Wennan Du; Chunhui Zhao; Jie Li; Jianbo Mao; Hao Chen; Lingyun Cheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-07       Impact factor: 4.799

6.  Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.

Authors:  K Ghasemi Falavarjani; M Hashemi; M Modarres; A Hadavand Khani
Journal:  Eye (Lond)       Date:  2014-02-21       Impact factor: 3.775

Review 7.  [Pharmacokinetics of intravitreally administered VEGF inhibitors].

Authors:  T U Krohne; F G Holz; C H Meyer
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

Review 8.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.

Authors:  K Ghasemi Falavarjani; Q D Nguyen
Journal:  Eye (Lond)       Date:  2013-05-31       Impact factor: 3.775

9.  Intravitreal bevacizumab for pseudophakic cystoid macular edema; a systematic review.

Authors:  Khalil Ghasemi Falavarjani; Mohammad-Mehdi Parvaresh; Mehdi Modarres; Masih Hashemi; Nasrollah Samiy
Journal:  J Ophthalmic Vis Res       Date:  2012-07

Review 10.  Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.

Authors:  Shivi Agrawal; Malav Joshi; John B Christoforidis
Journal:  Mediators Inflamm       Date:  2013-11-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.